Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer.

Jafari N, Drury J, Morris AJ, Onono FO, Stevens PD, Gao T, Liu J, Wang C, Lee EY, Weiss HL, Evers BM, Zaytseva YY.

Mol Cancer Res. 2019 Jan;17(1):140-152. doi: 10.1158/1541-7786.MCR-18-0199. Epub 2018 Aug 28.

PMID:
30154249
2.

Erbin Suppresses KSR1-Mediated RAS/RAF Signaling and Tumorigenesis in Colorectal Cancer.

Stevens PD, Wen YA, Xiong X, Zaytseva YY, Li AT, Wang C, Stevens AT, Farmer TN, Gan T, Weiss HL, Inagaki M, Marchetto S, Borg JP, Gao T.

Cancer Res. 2018 Sep 1;78(17):4839-4852. doi: 10.1158/0008-5472.CAN-17-3629. Epub 2018 Jul 6.

3.

Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer.

Zaytseva YY, Rychahou PG, Le AT, Scott TL, Flight RM, Kim JT, Harris J, Liu J, Wang C, Morris AJ, Sivakumaran TA, Fan T, Moseley H, Gao T, Lee EY, Weiss HL, Heuer TS, Kemble G, Evers M.

Oncotarget. 2018 May 15;9(37):24787-24800. doi: 10.18632/oncotarget.25361. eCollection 2018 May 15.

4.

Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.

Wang Q, Zhou Y, Rychahou P, Harris JW, Zaytseva YY, Liu J, Wang C, Weiss HL, Liu C, Lee EY, Evers BM.

Cancer Res. 2018 Jun 15;78(12):3163-3175. doi: 10.1158/0008-5472.CAN-17-3107. Epub 2018 Apr 17.

5.

Downregulation of SREBP inhibits tumor growth and initiation by altering cellular metabolism in colon cancer.

Wen YA, Xiong X, Zaytseva YY, Napier DL, Vallee E, Li AT, Wang C, Weiss HL, Evers BM, Gao T.

Cell Death Dis. 2018 Feb 15;9(3):265. doi: 10.1038/s41419-018-0330-6.

6.

Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles.

Rychahou P, Bae Y, Reichel D, Zaytseva YY, Lee EY, Napier D, Weiss HL, Roller N, Frohman H, Le AT, Mark Evers B.

J Control Release. 2018 Apr 10;275:85-91. doi: 10.1016/j.jconrel.2018.02.008. Epub 2018 Feb 6.

7.

Temperature induces significant changes in both glycolytic reserve and mitochondrial spare respiratory capacity in colorectal cancer cell lines.

Mitov MI, Harris JW, Alstott MC, Zaytseva YY, Evers BM, Butterfield DA.

Exp Cell Res. 2017 May 15;354(2):112-121. doi: 10.1016/j.yexcr.2017.03.046. Epub 2017 Mar 22.

8.

Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer.

Wen YA, Xing X, Harris JW, Zaytseva YY, Mitov MI, Napier DL, Weiss HL, Mark Evers B, Gao T.

Cell Death Dis. 2017 Feb 2;8(2):e2593. doi: 10.1038/cddis.2017.21.

9.

An obligatory role for neurotensin in high-fat-diet-induced obesity.

Li J, Song J, Zaytseva YY, Liu Y, Rychahou P, Jiang K, Starr ME, Kim JT, Harris JW, Yiannikouris FB, Katz WS, Nilsson PM, Orho-Melander M, Chen J, Zhu H, Fahrenholz T, Higashi RM, Gao T, Morris AJ, Cassis LA, Fan TW, Weiss HL, Dobner PR, Melander O, Jia J, Evers BM.

Nature. 2016 May 19;533(7603):411-5. doi: 10.1038/nature17662. Epub 2016 May 11.

10.

Increased expression of fatty acid synthase provides a survival advantage to colorectal cancer cells via upregulation of cellular respiration.

Zaytseva YY, Harris JW, Mitov MI, Kim JT, Butterfield DA, Lee EY, Weiss HL, Gao T, Evers BM.

Oncotarget. 2015 Aug 7;6(22):18891-904.

11.

Neurotensin, a novel target of Wnt/β-catenin pathway, promotes growth of neuroendocrine tumor cells.

Kim JT, Liu C, Zaytseva YY, Weiss HL, Townsend CM Jr, Evers BM.

Int J Cancer. 2015 Mar 15;136(6):1475-81. doi: 10.1002/ijc.29123. Epub 2014 Aug 14.

12.

Activation of c-Met and upregulation of CD44 expression are associated with the metastatic phenotype in the colorectal cancer liver metastasis model.

Elliott VA, Rychahou P, Zaytseva YY, Evers BM.

PLoS One. 2014 May 13;9(5):e97432. doi: 10.1371/journal.pone.0097432. eCollection 2014.

13.

Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer.

Zaytseva YY, Elliott VA, Rychahou P, Mustain WC, Kim JT, Valentino J, Gao T, O'Connor KL, Neltner JM, Lee EY, Weiss HL, Evers BM.

Carcinogenesis. 2014 Jun;35(6):1341-51. doi: 10.1093/carcin/bgu042. Epub 2014 Feb 7.

14.

Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.

Valentino JD, Li J, Zaytseva YY, Mustain WC, Elliott VA, Kim JT, Harris JW, Campbell K, Weiss H, Wang C, Song J, Anthony L, Townsend CM Jr, Evers BM.

Clin Cancer Res. 2014 Mar 1;20(5):1212-22. doi: 10.1158/1078-0432.CCR-13-1897. Epub 2014 Jan 17.

15.

Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.

Valentino JD, Elliott VA, Zaytseva YY, Rychahou PG, Mustain WC, Wang C, Gao T, Evers BM.

Surgery. 2012 Aug;152(2):277-85. doi: 10.1016/j.surg.2012.05.006.

16.

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.

Gulhati P, Zaytseva YY, Valentino JD, Stevens PD, Kim JT, Sasazuki T, Shirasawa S, Lee EY, Weiss HL, Dong J, Gao T, Evers BM.

Carcinogenesis. 2012 Sep;33(9):1782-90. doi: 10.1093/carcin/bgs203. Epub 2012 Jun 13.

17.

Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer.

Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O'Connor K, Morris AJ, Sunkara M, Weiss HL, Lee EY, Evers BM.

Cancer Res. 2012 Mar 15;72(6):1504-17. doi: 10.1158/0008-5472.CAN-11-4057. Epub 2012 Jan 19.

18.

mTOR inhibitors in cancer therapy.

Zaytseva YY, Valentino JD, Gulhati P, Evers BM.

Cancer Lett. 2012 Jun 1;319(1):1-7. doi: 10.1016/j.canlet.2012.01.005. Epub 2012 Jan 17. Review.

PMID:
22261336
19.

The effect of PTEN on serotonin synthesis and secretion from the carcinoid cell line BON.

Silva SR, Zaytseva YY, Jackson LN, Lee EY, Weiss HL, Bowen KA, Townsend CM Jr, Evers BM.

Anticancer Res. 2011 Apr;31(4):1153-60.

20.
21.

Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells.

Zaytseva YY, Wang X, Southard RC, Wallis NK, Kilgore MW.

Mol Cancer. 2008 Dec 5;7:90. doi: 10.1186/1476-4598-7-90.

22.

Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells.

Talbert DR, Allred CD, Zaytseva YY, Kilgore MW.

Breast Cancer Res Treat. 2008 Mar;108(1):23-33. Epub 2007 Apr 24.

PMID:
17453334

Supplemental Content

Loading ...
Support Center